2-((3-(4-Hydroxy-3-methoxybenzyl)thioureido)methyl)-3-(3,4-dimethylphenyl)propyl pivalate

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-((3-(4-Hydroxy-3-methoxybenzyl)thioureido)methyl)-3-(3,4-dimethylphenyl)propyl pivalate
• 英文别名: [2-[(3,4-dimethylphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methylcarbamothioylamino]propyl] 2,2-dimethylpropanoate
• 化学式: C₂₆H₃₆N₂O₄S
• 分子量: 472.6
• InChiKey: KDYVIORLSJSMTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  33
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE
  申请人：Nocion Therapeutics, Inc.

  公开号：US20210128589A1

  公开（公告）日：2021-05-06

  The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

  本发明提供了式(I)的化合物，或其药用可接受的盐： 本发明的化合物、组合物、方法和试剂盒可用于治疗疼痛、瘙痒和神经性炎症。
• [EN] P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS P2X3 ET/OU P2X2/3 ET MÉTHODES ASSOCIÉES
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2018064135A1

  公开（公告）日：2018-04-05

  The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.

  本公开提供了新颖的化合物和制备和使用这些化合物的方法。在一种实施例中，这些化合物具有如下式（I）的结构，其中R1-R7在此处定义。在另一种实施例中，这些化合物在调节P2X3或P2X2/3受体中的一种或两种的方法中是有用的。在另一种实施例中，通过向患者施用一种或多种化合物来治疗患者的疼痛是有用的。在另一种实施例中，通过向患者施用一种或多种化合物来治疗患者的呼吸功能障碍是有用的。
• [EN] P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS DE P2X3 ET/OU P2X2/3 ET PROCÉDÉS
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015095128A1

  公开（公告）日：2015-06-25

  The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

  本申请提供了新颖的化合物以及制备和使用这些化合物的方法。在一个实施例中，这些化合物具有如下式（I）的结构，其中R1-R4在此处被定义。在另一个实施例中，这些化合物在调节P2X3或P2X2/3受体中的一个或两个的方法中是有用的。在另一个实施例中，这些化合物通过向患者施用一个或多个化合物来治疗患者的疼痛是有用的。
• Cyclohexylamines
  申请人：Endo Pharmaceuticals, Inc.

  公开号：US20130101667A1

  公开（公告）日：2013-04-25

  The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.

  本申请提供了新颖的化合物以及制备和使用这些化合物的方法。这些化合物在治疗疼痛、瘙痒、膀胱过度活跃和/或间质性膀胱炎患者中是有用的，通过向患者施用一个或多个这些化合物。这些方法包括给患者施用式(I)的化合物和TRPV1受体激活剂。在一个实施例中，TRPV1受体激活剂是利多卡因。
• Aminoindane Compounds and Use Thereof in Treating Pain
  申请人：Thompson Scott Kevin

  公开号：US20120214809A1

  公开（公告）日：2012-08-23

  The present application provides novel aminoindane compounds and methods for preparing and using these compounds. These compounds are useful in treating pain and/or itch in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) or (II) and a TRPV 1 receptor activator. In one embodiment, the TRPV 1 receptor activator is lidocaine.

  本申请提供了新颖的氨基茚化合物以及制备和使用这些化合物的方法。这些化合物可用于通过向患者施用一种或多种化合物来治疗患者的疼痛和/或瘙痒。这些方法包括施用式(I)或(II)的化合物和TRPV 1受体激活剂。在一个实施例中，TRPV 1受体激活剂是利多卡因。